提示: 手机请竖屏浏览!

Depression in the Primary Care Setting

Lawrence T. Park ... 其他 • 2019.02.07
• 青少年抑郁症 • 肥胖是抑郁的病因之一 • 艾氯胺酮治疗难治性抑郁症——美国FDA批准首种新型抗抑郁药 • 体育活动用于治疗青少年和年轻成人抑郁症患者 • 抑郁症和卒中



Lawrence T. Park, M.D., and Carlos A. Zarate, Jr., M.D.
From the Section on the Neurobiology and Treatment of Mood Disorders, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD. Address reprint requests to Dr. Park at 10 Center Dr., MSC 1282, Bldg. 10 CRC, Rm. 7-3465, Bethesda, MD 20892-1282, or at lawrence.park@nih.gov.



1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545-1602.

2. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012;21:169-184.

3. Henriksson MM, Aro HM, Marttunen MJ, et al. Mental disorders and comorbidity in suicide. Am J Psychiatry 1993;150:935-940.

4. Health, United States, 2016: with chartbook on long-term trends in health. Hyattsville, MD: National Center for Health Statistics, 2017.

5. Diagnostic and statistical manual of mental disorders, 5th ed.: DSM-V. Washington, DC: American Psychiatric Association, 2013.

6. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008;455:894-902.

7. Burke KC, Burke JD Jr, Regier DA, Rae DS. Age at onset of selected mental disorders in five community populations. Arch Gen Psychiatry 1990;47:511-518.

8. Eaton WW, Anthony JC, Gallo J, et al. Natural history of diagnostic interview schedule/DSM-IV major depression: the Baltimore Epidemiologic Catchment Area follow-up. Arch Gen Psychiatry 1997;54:993-999.

9. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105.

10. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-299.

11. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-351.

12. Frank RG, Huskamp HA, Pincus HA. Aligning incentives in the treatment of depression in primary care with evidence-based practice. Psychiatr Serv 2003;54:682-687.

13. Mark TL, Levit KR, Buck JA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv 2009;60:1167-1167.

14. Ahmedani BK, Stewart C, Simon GE, et al. Racial/ethnic differences in health care visits made before suicide attempt across the United States. Med Care 2015;53:430-435.

15. Sartorius N. Stigma and mental health. Lancet 2007;370:810-811.

16. Siu AL, Bibbins-Domingo K, Grossman DC, et al. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA 2016;315:380-387.

17. A follow-up report on preventing suicide: focus on medical/surgical units and the emergency department. Sentinel Event Alert 2010;46:1-4.

18. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003;41:1284-1292.

19. Arroll B, Goodyear-Smith F, Crengle S, et al. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med 2010;8:348-353.

20. Horowitz LM, Snyder D, Ludi E, et al. Ask Suicide-Screening Questions to everyone in medical settings: the asQ’em Quality Improvement Project. Psychosomatics 2013;54:239-247.

21. Jiao B, Rosen Z, Bellanger M, Belkin G, Muennig P. The cost-effectiveness of PHQ screening and collaborative care for depression in New York City. PLoS One 2017;12(8):e0184210-e0184210.

22. Denchev P, Pearson JL, Allen MH, et al. Modeling the cost-effectiveness of interventions to reduce suicide risk among hospital emergency department patients. Psychiatr Serv 2018;69:23-31.

23. Cassem NH, Papakostas GI, Fava M, Stern TA. Mood-disorder patients. In: Stern TA, Cassem NH, Fricchione G, Rosenbaum JF, Jellinek M, eds. Massachusetts General Hospital handbook of general hospital psychiatry. 5th ed. Philadelphia: Mosby, 2004:69-92.

24. Cassem NH, Murray GB, Lafayette JM, Stern TA. Delirious patients. In: Stern TA, Cassem NH, Fricchione G, Rosenbaum JF, Jellinek M, eds. Massachusetts General Hospital handbook of general hospital psychiatry. 5th ed. Philadelphia: Mosby, 2004:119-134.

25. Rogers D, Pies R. General medical with depression drugs associated. Psychiatry (Edgmont) 2008;5:28-41.

26. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537.

27. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010;71:Suppl E1:e04-e04.

28. Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997;54:1009-1015.

29. Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol 2008;76:909-922.

30. Cuijpers P, Karyotaki E, Weitz E, Andersson G, Hollon SD, van Straten A. The effects of psychotherapies for major depression in adults on remission, recovery and improvement: a meta-analysis. J Affect Disord 2014;159:118-126.

31. Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A, Dobson KS. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry 2013;58:376-385.

32. Cuijpers P, Cristea IA, Karyotaki E, Reijnders M, Huibers MJ. How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry 2016;15:245-258.

33. Simon GE, Ludman EJ, Tutty S, Operskalski B, Von Korff M. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. JAMA 2004;292:935-942.

34. Arnberg FK, Linton SJ, Hultcrantz M, Heintz E, Jonsson U. Internet-delivered psychological treatments for mood and anxiety disorders: a systematic review of their efficacy, safety, and cost-effectiveness. PLoS One 2014;9(5):e98118-e98118.

35. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5(2):e45-e45.

36. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.

37. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917.

38. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009;60:1439-1445.

39. Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012;37:851-864.

40. Saveanu R, Etkin A, Duchemin AM, et al. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res 2015;61:1-12.

41. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391:1357-1366.

42. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Section 3. Pharmacological treatments. Can J Psychiatry 2016;61:540-560.

43. Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists’ selection of antidepressants? Am J Psychiatry 2004;161:1285-1289.

44. APA Work Group on Psychiatric Evaluation. The American Psychiatric Association practice guidelines for the psychiatric evaluation of adults. 3rd ed. Arlington, VA: American Psychiatric Association, 2016.

Google Scholar

45. Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry 2009;70:1219-1229.

46. Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Duration of initial antidepressant treatment and subsequent relapse of major depression. J Clin Psychopharmacol 2015;35:75-76.

47. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117:Suppl 1:S26-S43.

48. Piccinelli M, Wilkinson G. Outcome of depression in psychiatric settings. Br J Psychiatry 1994;164:297-304.

49. Arnow BA, Blasey C, Williams LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatry 2015;172:743-750.

50. Drysdale AT, Grosenick L, Downar J, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med 2017;23:28-38.

51. Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 2018;50:668-681.

52. Green E, Goldstein-Piekarski AN, Schatzberg AF, Rush AJ, Ma J, Williams L. Personalizing antidepressant choice by sex, body mass index, and symptoms profile: an iSPOT-D report. Pers Med Psychiatry 2017;1-2:65-73.

53. Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry 2017;78:720-729.

54. Lam RW, Kennedy SH, Parikh SV, MacQueen GM, Milev RV, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods. Can J Psychiatry 2016;61:506-509.

55. National Institute for Health and Care Excellence. Depression in adults: recognition and management 2009. October 2009 (https://www.nice.org.uk/guidance/cg90).

服务条款 | 隐私政策 | 联系我们